Leveraging Immunogenic Subtypes of High-Grade Serous Ovarian Cancer for Improved Therapy Selection

Project summary

Our research aims to improve survival rates for high-grade serous ovarian cancer (HGSC) patients by identifying those most likely to derive clinical benefit from immunotherapy. We previously identified a group of genes, “STRATsig,” which classifies HGSC tumors based on their immunogenicity. By using patient-derived tumor organoids PTOs, our approach is unique in its ability to test new treatments directly on tumor cells. Using STRATsig group defined PTOs, we hope to identify not only a group of HGSC tumors that may respond to immunotherapies, but also to discover novel ways to overcome immunotherapy resistance.